Sara M Tolaney (S M Tolaney, Sara Tolaney)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 135

Top Venues

NPJ breast cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Nature communications

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Jorge Gomez Tejeda Zanudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa M Pereslete, Daniel L Abravanel, Arlindo R Ferreira, Eileen Wrabel, Karla Helvie, Melissa E Hughes, Ann H Partridge, Beth A Overmoyer, Nancy U Lin, Nabihah Tayob, Sara M Tolaney, Nikhil Wagle
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature communications 15 (1) (2024)
Jennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, Zi-Ming Du, Yu-An Chen, Madeline G Townsend, Kenichi Shimada, Melissa E Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L Taneja, Otto Metzger, Sara M Tolaney, Nancy U Lin, Deborah A Dillon, Stuart J Schnitt, Peter K Sorger, Elizabeth A Mittendorf, Sandro Santagata
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ breast cancer 10 (1) (2024)
Sara M Tolaney, Angela DeMichele, Toshimi Takano, Hope S Rugo, Charles Perou, Filipa Lynce, Heather Anne Parsons, Cesar Augusto Santa-Maria, Gabrielle Betty Rocque, Wenliang Yao, Shawn W Sun, Simonetta Mocci, Ann H Partridge, Lisa A Carey
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future oncology (London, England) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Paolo Tarantino, Julieta Leone, Carlos T Vallejo, Rachel A Freedman, Adrienne G Waks, Olga Martínez-Sáez, Ana Christina Garrido-Castro, Filipa C Lynce, Nabihah Tayob, Nancy U Lin, Sara M Tolaney, José Pablo Leone
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley, Steven Jay Isakoff, Vicente Valero, Meredith Faggen, Therese Marie Mulvey, Ron Bose, Douglas Weckstein, Antonio C Wolff, Katherine E Reeder-Hayes, Hope S Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K Gadi, Michael Constantine, Kit Cheng, Audrey Merrill Garrett, P Kelly Marcom, Kathy S Albain, Patricia DeFusco, Nadine M Tung, Blair Ardman, Rita Nanda, Rachel C Jankowitz, Mothaffar F Rimawi, Vandana G Abramson, Paula R Pohlmann, Catherine H Van Poznak, Andres Forero-Torres, Minetta C Liu, Kathryn J Ruddy, Adrienne G Waks, Michelle DeMeo, Harold J Burstein, Ann H Partridge, Patrizia Dell'Orto, Leila Russo, Emma Krause, Daniel J Newhouse, Busem Binboğa Kurt, Elizabeth A Mittendorf, Bryan Paul Schneider, Adrienne G Waks, Eric P Winer, Ian E Krop, Sara M Tolaney, null null, null null
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Jorge Gomez Tejeda Zanudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa M Pereslete, Daniel L Abravanel, Arlindo R Ferreira, Eileen Wrabel, Karla Helvie, Melissa E Hughes, Ann H Partridge, Beth A Overmoyer, Nancy U Lin, Nabihah Tayob, Sara M Tolaney, Nikhil Wagle
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature communications 15 (1) (2024)
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partridge, Brittany L Bychkovsky, Curigliano Giuseppe, Nabihah Tayob, Nancy U Lin, Judy E Garber, Sara M Tolaney, Filipa C Lynce
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ breast cancer 10 (1) (2024)
Bojana Jovanovic, Sarah E Church, Kara M Gorman, Khrystyna North, Edward T Richardson, Molly DiLullo, Victoria Attaya, Julie Kasparian, Ayesha Mohammed-Abreu, Gregory Kirkner, Melissa E Hughes, Nancy U Lin, Elizabeth A Mittendorf, Stuart J Schnitt, Sara M Tolaney, Shom Goel
Integrative multi-omic profiling of triple-negative breast cancer for identifying suitable therapies. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Stefania Morganti, Christopher J Gibson, Qingchun Jin, Katheryn Santos, Ashka Patel, Alex Wilson, Margaret Merrill, Julie Vincuilla, Samantha Stokes, Marla Lipsyc-Sharf, Tonia Parker, Tari A King, Elizabeth A Mittendorf, Curigliano Giuseppe, Melissa E Hughes, Daniel G Stover, Sara M Tolaney, Lachelle Dawn Weeks, Nabihah Tayob, Nancy U Lin, Judy E Garber, Peter Grant Miller, Heather A Parsons
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Jennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, Zi-Ming Du, Yu-An Chen, Madeline G Townsend, Kenichi Shimada, Melissa E Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L Taneja, Otto Metzger, Sara M Tolaney, Nancy U Lin, Deborah A Dillon, Stuart J Schnitt, Peter K Sorger, Elizabeth A Mittendorf, Sandro Santagata
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ breast cancer 10 (1) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partridge, Brittany L Bychkovsky, Curigliano Giuseppe, Nabihah Tayob, Nancy U Lin, Judy E Garber, Sara M Tolaney, Filipa C Lynce
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ breast cancer 10 (1) (2024)
Jorge Gomez Tejeda Zanudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa M Pereslete, Daniel L Abravanel, Arlindo R Ferreira, Eileen Wrabel, Karla Helvie, Melissa E Hughes, Ann H Partridge, Beth A Overmoyer, Nancy U Lin, Nabihah Tayob, Sara M Tolaney, Nikhil Wagle
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature communications 15 (1) (2024)
Jonathan Goldberg, Na Qiao, Jennifer L Guerriero, Brett Gross, Yagiz Meneksedag, Yoshimi F Lu, Anne V Philips, Tasnim Rahman, Funda Meric-Bernstam, Jason Roszik, Ken Chen, Rinath M Jeselsohn, Sara M Tolaney, George E Peoples, Gheath Al-Atrash, Elizabeth A Mittendorf
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-Positive Breast Cancer. Cancer research communications (2024)
Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida, Victoria Attaya, Victoria Attaya, Ibrahim M Abbass, Anita Fung, Jesse Sussell, Patricia Cortazar, Caroline Harvey, Denise Leth, Meredith Faggen, Natalie Sinclair, Jeanna Walsh, Nadine M Tung, Sarah Sinclair, Steve Lo, Denise Yardley, Vicente Valero, Jane Meisel, Tarah Jean Ballinger, Sylvia Adams, Lisa Anne Carey, Julia K Rauch, Vandana G Abramson, Nicole O Williams, Wendy Y Chen, José Pablo Leone, Susan T Schumer, Nabihah Tayob, Sara M Tolaney
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial). JCO oncology practice (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Paolo Tarantino, Julieta Leone, Carlos T Vallejo, Rachel A Freedman, Adrienne G Waks, Olga Martínez-Sáez, Ana Christina Garrido-Castro, Filipa C Lynce, Nabihah Tayob, Nancy U Lin, Sara M Tolaney, José Pablo Leone
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Adrienne G Waks, Olga Martínez-Sáez, Paolo Tarantino, Fara Braso-Maristany, Tomás Pascual, Javier Cortes, Sara M Tolaney, Aleix Prat
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. Nature reviews. Clinical oncology (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma L Mahtani, Cynthia X Ma, Angela M DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara G Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya A Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Y Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M Tolaney
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partridge, Brittany L Bychkovsky, Curigliano Giuseppe, Nabihah Tayob, Nancy U Lin, Judy E Garber, Sara M Tolaney, Filipa C Lynce
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer. NPJ breast cancer 10 (1) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Paolo Tarantino, Julieta Leone, Carlos T Vallejo, Rachel A Freedman, Adrienne G Waks, Olga Martínez-Sáez, Ana Christina Garrido-Castro, Filipa C Lynce, Nabihah Tayob, Nancy U Lin, Sara M Tolaney, José Pablo Leone
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Stefania Morganti, Christopher J Gibson, Qingchun Jin, Katheryn Santos, Ashka Patel, Alex Wilson, Margaret Merrill, Julie Vincuilla, Samantha Stokes, Marla Lipsyc-Sharf, Tonia Parker, Tari A King, Elizabeth A Mittendorf, Curigliano Giuseppe, Melissa E Hughes, Daniel G Stover, Sara M Tolaney, Lachelle Dawn Weeks, Nabihah Tayob, Nancy U Lin, Judy E Garber, Peter Grant Miller, Heather A Parsons
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Jonathan Goldberg, Na Qiao, Jennifer L Guerriero, Brett Gross, Yagiz Meneksedag, Yoshimi F Lu, Anne V Philips, Tasnim Rahman, Funda Meric-Bernstam, Jason Roszik, Ken Chen, Rinath M Jeselsohn, Sara M Tolaney, George E Peoples, Gheath Al-Atrash, Elizabeth A Mittendorf
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer. Cancer research communications 4 (2) (2024)
Jonathan Goldberg, Na Qiao, Jennifer L Guerriero, Brett Gross, Yagiz Meneksedag, Yoshimi F Lu, Anne V Philips, Tasnim Rahman, Funda Meric-Bernstam, Jason Roszik, Ken Chen, Rinath M Jeselsohn, Sara M Tolaney, George E Peoples, Gheath Al-Atrash, Elizabeth A Mittendorf
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer. Cancer research communications 4 (2) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Jorge Gomez Tejeda Zanudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa M Pereslete, Daniel L Abravanel, Arlindo R Ferreira, Eileen Wrabel, Karla Helvie, Melissa E Hughes, Ann H Partridge, Beth A Overmoyer, Nancy U Lin, Nabihah Tayob, Sara M Tolaney, Nikhil Wagle
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nature communications 15 (1) (2024)
Jennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, Zi-Ming Du, Yu-An Chen, Madeline G Townsend, Kenichi Shimada, Melissa E Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L Taneja, Otto Metzger, Sara M Tolaney, Nancy U Lin, Deborah A Dillon, Stuart J Schnitt, Peter K Sorger, Elizabeth A Mittendorf, Sandro Santagata
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ breast cancer 10 (1) (2024)
Jennifer L Guerriero, Jia-Ren Lin, Ricardo G Pastorello, Zi-Ming Du, Yu-An Chen, Madeline G Townsend, Kenichi Shimada, Melissa E Hughes, Siyang Ren, Nabihah Tayob, Kelly Zheng, Shaolin Mei, Alyssa Patterson, Krishan L Taneja, Otto Metzger, Sara M Tolaney, Nancy U Lin, Deborah A Dillon, Stuart J Schnitt, Peter K Sorger, Elizabeth A Mittendorf, Sandro Santagata
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer. NPJ breast cancer 10 (1) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Jonathan Goldberg, Na Qiao, Jennifer L Guerriero, Brett Gross, Yagiz Meneksedag, Yoshimi F Lu, Anne V Philips, Tasnim Rahman, Funda Meric-Bernstam, Jason Roszik, Ken Chen, Rinath M Jeselsohn, Sara M Tolaney, George E Peoples, Gheath Al-Atrash, Elizabeth A Mittendorf
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer. Cancer research communications 4 (2) (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma L Mahtani, Cynthia X Ma, Angela M DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara G Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya A Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Y Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M Tolaney
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (17) (2024)
Matthew P Goetz, Irfan Cicin, Laura Testa, Sara M Tolaney, Jens Huober, Valentina Guarneri, Stephen R D Johnston, Miguel Martin, Priya Rastogi, Nadia Harbeck, Ashwin Shahir, Ran Wei, Valérie André, Hope S Rugo, Joyce O'Shaughnessy
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ breast cancer 10 (1) (2024)
Fei Song, Paolo Tarantino, Ana Garrido-Castro, Filipa C Lynce, Sara M Tolaney, Ilana Schlam
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better? Current oncology reports 26 (1) (2024)
Antonio Giordano, Priya U Kumthekar, Qingchun Jin, Busem Binboğa Kurt, Siyang Ren, Tianyu Li, José Pablo Leone, Elizabeth A Mittendorf, Alyssa M Pereslete, Laura Sharp, Raechel Davis, Molly DiLullo, Nabihah Tayob, Erica L Mayer, Eric P Winer, Sara M Tolaney, Nancy U Lin
A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Stefania Morganti, Christopher J Gibson, Qingchun Jin, Katheryn Santos, Ashka Patel, Alex Wilson, Margaret Merrill, Julie Vincuilla, Samantha Stokes, Marla Lipsyc-Sharf, Tonia Parker, Tari A King, Elizabeth A Mittendorf, Curigliano Giuseppe, Melissa E Hughes, Daniel G Stover, Sara M Tolaney, Lachelle Dawn Weeks, Nabihah Tayob, Nancy U Lin, Judy E Garber, Peter Grant Miller, Heather A Parsons
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma L Mahtani, Cynthia X Ma, Angela M DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara G Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya A Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Y Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M Tolaney
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (17) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Matthew P Goetz, Irfan Cicin, Laura Testa, Sara M Tolaney, Jens Huober, Valentina Guarneri, Stephen R D Johnston, Miguel Martin, Priya Rastogi, Nadia Harbeck, Ashwin Shahir, Ran Wei, Valérie André, Hope S Rugo, Joyce O'Shaughnessy
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Sheng Sun, Nayana Thimmiah, James T T Coates, Bogang Wu, Rachel Occhiogrosso Abelman, Laura M Spring, Beverly Moy, Phoebe Ryan, Mark N Melkonyan, Ann H Partridge, Dejan Juric, Jeffrey M Peppercorn, Heather A Parsons, Seth A Wander, Victoria Attaya, Brenda Lormil, Maria Shellock, Aiko Nagayama, Veerle Bossuyt, Steven Jay Isakoff, Sara M Tolaney, Leif W Ellisen
Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Sylvan C Baca, Ji-Heui Seo, Matthew P Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian, Gitanjali Lakshminarayanan, Miklos Diossy, Xintao Qiu, Talal El Zarif, Hunter Savignano, John Canniff, Ikenna Madueke, Renee Maria Saliby, Ziwei Zhang, Rong Li, Yijia Jiang, Len Taing, Mark Awad, Cindy H Chau, James A Decaprio, William Douglas Figg, Tim F Greten, Aaron N Hata, F Stephen Hodi, Melissa E Hughes, Keith L Ligon, Nancy Lin, Kimmie Ng, Matthew G Oser, Catherine Meador, Heather A Parsons, Mark M Pomerantz, Arun Rajan, Jerome Ritz, Manisha Thakuria, Sara M Tolaney, Patrick Y Wen, Henry W Long, Jacob E Berchuck, Zoltan Szallasi, Toni K Choueiri, Matthew L Freedman
Liquid biopsy epigenomic profiling for cancer subtyping. Nature medicine (2023)
Hope S Rugo, Aditya Bardia, Sara M Tolaney
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Kimia Sorouri, Filipa C Lynce, Colleen M Feltmate, Michelle R Davis, Michael G Muto, Panagiotis A Konstantinopoulos, Elizabeth H Stover, Allison W Kurian, Sarah J Hill, Ann H Partridge, Sara M Tolaney, Judy E Garber, Brittany L Bychkovsky
Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps. JCO precision oncology 7 (2023)
Lestat R Ali, Ana Christina Garrido-Castro, Patrick J Lenehan, Naima Bollenrucher, Courtney T S Kureshi, Michael L Dougan, Shom Goel, Geoffrey I Shapiro, Sara M Tolaney, Stephanie K Dougan
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. The Journal of experimental medicine 220 (4) (2023)
Sara M Tolaney, Shom Goel, Jorge Nadal, Hannelore G Denys, Manuel Ruiz Borrego, Lacey M Litchfield, Jiangang Liu, Adams K Appiah, Yanyun Chen, Fabrice Andre
Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant vs trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Albert Grinshpun, Sara M Tolaney, Harold J Burstein, Rinath M Jeselsohn, Erica L Mayer
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Laura Alder, Dario Trapani, Claire Bradbury, Amanda E D Van Swearingen, Sara M Tolaney, Mustafa Khasraw, Carey K Anders, Christopher D Lascola, Liangge Hsu, Nancy U Lin, Sarah L Sammons
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. NPJ breast cancer 9 (1) (2023)
Laura Alder, Dario Trapani, Claire Bradbury, Amanda E D Van Swearingen, Sara M Tolaney, Mustafa Khasraw, Carey K Anders, Christopher D Lascola, Liangge Hsu, Nancy U Lin, Sarah L Sammons
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. NPJ breast cancer 9 (1) (2023)
Arika S Feils, Amy K Erbe, Jennifer Birstler, KyungMann Kim, U Hoch, S L Currie, T Nguyen, D Yu, Arlene O Siefker-Radtke, Nizar M Tannir, Sara M Tolaney, Adi Diab, Paul M Sondel
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. Cancer immunology, immunotherapy : CII (2023)
Sara M Tolaney, Elisabeth De Kermadec, Patrick Cohen, Gautier Paux, Lei Wang, Seock-Ah Im
Reply to Y. Yoshitomi et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Hope S Rugo, Aditya Bardia, Sara M Tolaney
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Lestat R Ali, Ana Christina Garrido-Castro, Patrick J Lenehan, Naima Bollenrucher, Courtney T S Kureshi, Michael L Dougan, Shom Goel, Geoffrey I Shapiro, Sara M Tolaney, Stephanie K Dougan
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. The Journal of experimental medicine 220 (4) (2023)
Lestat R Ali, Ana Christina Garrido-Castro, Patrick J Lenehan, Naima Bollenrucher, Courtney T S Kureshi, Michael L Dougan, Shom Goel, Geoffrey I Shapiro, Sara M Tolaney, Stephanie K Dougan
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. The Journal of experimental medicine 220 (4) (2023)
Kimia Sorouri, Filipa C Lynce, Colleen M Feltmate, Michelle R Davis, Michael G Muto, Panagiotis A Konstantinopoulos, Elizabeth H Stover, Allison W Kurian, Sarah J Hill, Ann H Partridge, Sara M Tolaney, Judy E Garber, Brittany L Bychkovsky
Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps. JCO precision oncology 7 (2023)
Sara M Tolaney, Arlene Chan, Katarina Petrakova, Suzette Delaloge, Mario Campone, Hiroji Iwata, Parvin F Peddi, Peter A Kaufman, Elisabeth De Kermadec, Qianying Liu, Patrick Cohen, Gautier Paux, Lei Wang, Nils Ternès, Eric Boitier, Seock-Ah Im
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Lestat R Ali, Ana Christina Garrido-Castro, Patrick J Lenehan, Naima Bollenrucher, Courtney T S Kureshi, Michael L Dougan, Shom Goel, Geoffrey I Shapiro, Sara M Tolaney, Stephanie K Dougan
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. The Journal of experimental medicine 220 (4) (2023)
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana Christina Garrido-Castro, Romualdo Barroso-Sousa, Brittany L Bychkovsky, Simona DiLascio, Lynette M Sholl, Laura MacConaill, Neal Lindeman, Bruce E Johnson, Matthew L Meyerson, Rinath M Jeselsohn, Xintao Qiu, Rong Li, Henry W Long, Eric P Winer, Deborah Dillon, Curigliano Giuseppe, Andrew D Cherniack, Sara M Tolaney, Nancy U Lin
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature communications 14 (1) (2023)
Romualdo Barroso-Sousa, Jana Priscila Pacífico, Sarah Sammons, Sara M Tolaney
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities. Cancers 15 (15) (2023)
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana Christina Garrido-Castro, Romualdo Barroso-Sousa, Brittany L Bychkovsky, Simona DiLascio, Lynette M Sholl, Laura MacConaill, Neal Lindeman, Bruce E Johnson, Matthew L Meyerson, Rinath M Jeselsohn, Xintao Qiu, Rong Li, Henry W Long, Eric P Winer, Deborah Dillon, Curigliano Giuseppe, Andrew D Cherniack, Sara M Tolaney, Nancy U Lin
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature communications 14 (1) (2023)
Ana Christina Garrido-Castro, Meredith M Regan, Samuel M Niman, Faina Nakhlis, Claire Remolano, Jennifer M Rosenbluth, Caroline Block, Laura E G Warren, Jennifer R Bellon, Eren Yeh, Beth T Harrison, Elizabeth Troll, Nancy U Lin, Sara M Tolaney, Beth A Overmoyer, Filipa C Lynce
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. NPJ breast cancer 9 (1) (2023)
Dario Trapani, Qingchun Jin, Caroline C Block, Rachel A Freedman, Nancy U Lin, Paolo Tarantino, Elizabeth A Mittendorf, Tari A King, Susan C Lester, Jane E Brock, Nabihah Tayob, Craig A Bunnell, Sara M Tolaney, Harold J Burstein
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. JCO oncology practice (2023)
Laura Alder, Dario Trapani, Claire Bradbury, Amanda E D Van Swearingen, Sara M Tolaney, Mustafa Khasraw, Carey K Anders, Christopher D Lascola, Liangge Hsu, Nancy U Lin, Sarah L Sammons
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. NPJ breast cancer 9 (1) (2023)
Laura Alder, Dario Trapani, Claire Bradbury, Amanda E D Van Swearingen, Sara M Tolaney, Mustafa Khasraw, Carey K Anders, Christopher D Lascola, Liangge Hsu, Nancy U Lin, Sarah L Sammons
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. NPJ breast cancer 9 (1) (2023)
Lestat R Ali, Ana Christina Garrido-Castro, Patrick J Lenehan, Naima Bollenrucher, Courtney T S Kureshi, Michael L Dougan, Shom Goel, Geoffrey I Shapiro, Sara M Tolaney, Stephanie K Dougan
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. The Journal of experimental medicine 220 (4) (2023)
Paolo Tarantino, Sara M Tolaney
Detecting and Managing T-DXd-Related Interstitial Lung Disease: The Five "S" Rules. JCO oncology practice (2023)
Kimia Sorouri, Filipa C Lynce, Colleen M Feltmate, Michelle R Davis, Michael G Muto, Panagiotis A Konstantinopoulos, Elizabeth H Stover, Allison W Kurian, Sarah J Hill, Ann H Partridge, Sara M Tolaney, Judy E Garber, Brittany L Bychkovsky
Endometrial Cancer Risk Among Germline BRCA1 / 2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps. JCO precision oncology 7 (2023)
Albert Grinshpun, Sara M Tolaney, Harold J Burstein, Rinath M Jeselsohn, Erica L Mayer
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer. NPJ breast cancer 9 (1) (2023)
Francisco Hermida-Prado, Yingtian Xie, Shira Sherman, Zsuzsanna Nagy, Douglas Russo, Tara Akhshi, Zhengtao Chu, Avery Feit, Marco Campisi, Minyue Chen, Agostina Nardone, Cristina Guarducci, Klothilda Lim, Alba Font-Tello, Irene I Lee, Juana María García-Pedrero, Israel Cañadas, Judith Agudo, Ying Huang, Tal Sella, Qingchun Jin, Nabihah Tayob, Elizabeth A Mittendorf, Sara M Tolaney, Xintao Qiu, Henry W Long, William Fraser Symmans, Jia-Ren Lin, Sandro Santagata, Isabelle Bedrosian, Denise A Yardley, Ingrid A Mayer, Edward T Richardson, Giacomo Oliveira, Catherine J Wu, Eugene F Schuster, Mitchell Dowsett, Alana L Welm, David A Barbie, Otto Metzger Filho, Rinath M Jeselsohn
Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer. Cancer research (2023)
Paolo Tarantino, Hersh Gupta, Melissa E Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana Christina Garrido-Castro, Romualdo Barroso-Sousa, Brittany L Bychkovsky, Simona DiLascio, Lynette M Sholl, Laura MacConaill, Neal Lindeman, Bruce E Johnson, Matthew L Meyerson, Rinath M Jeselsohn, Xintao Qiu, Rong Li, Henry W Long, Eric P Winer, Deborah Dillon, Curigliano Giuseppe, Andrew D Cherniack, Sara M Tolaney, Nancy U Lin
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature communications 14 (1) (2023)
Lestat R Ali, Ana Christina Garrido-Castro, Patrick J Lenehan, Naima Bollenrucher, Courtney T S Kureshi, Michael L Dougan, Shom Goel, Geoffrey I Shapiro, Sara M Tolaney, Stephanie K Dougan
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. The Journal of experimental medicine 220 (4) (2023)
Paolo Tarantino, H Gupta, M E Hughes, J Files, S Strauss, G Kirkner, A-M Feeney, Y Li, Ana Christina Garrido-Castro, R Barroso-Sousa, Brittany L Bychkovsky, S DiLascio, Lynette M Sholl, L MacConaill, N Lindeman, B E Johnson, Matthew L Meyerson, Rinath M Jeselsohn, Xintao Qiu, Rong Li, Henry W Long, E P Winer, D Dillon, Curigliano Giuseppe, A D Cherniack, Sara M Tolaney, N U Lin
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. Nature communications 14 (1) (2023)
Sylvan C Baca, Ji-Heui Seo, Matthew P Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian, Gitanjali Lakshminarayanan, Miklos Diossy, Xintao Qiu, Talal El Zarif, Hunter Savignano, John Canniff, Ikenna Madueke, Renee Maria Saliby, Ziwei Zhang, Rong Li, Yijia Jiang, Len Taing, Mark Awad, Cindy H Chau, James A Decaprio, William Douglas Figg, Tim F Greten, Aaron N Hata, F Stephen Hodi, Melissa E Hughes, Keith L Ligon, Nancy Lin, Kimmie Ng, Matthew G Oser, Catherine Meador, Heather A Parsons, Mark M Pomerantz, Arun Rajan, Jerome Ritz, Manisha Thakuria, Sara M Tolaney, Patrick Y Wen, Henry W Long, Jacob E Berchuck, Zoltan Szallasi, Toni K Choueiri, Matthew L Freedman
Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping. Nature medicine (2023)
Jennifer K Litton, Meredith M Regan, Lajos Pusztai, Hope S Rugo, Sara M Tolaney, Elizabeth Garrett-Mayer, Laleh Amiri-Kordestani, Reva K Basho, Ana F Best, Jean-Francois Boileau, Carsten Denkert, Jared C Foster, Nadia Harbeck, Heather A Jacene, Tari A King, Ginny Mason, Ciara Catherine O'Sullivan, Tatiana M Prowell, Andrea L Richardson, Karla A Sepulveda, Mary Lou Smith, Judy A Tjoe, Gulisa Turashvili, Wendy A Woodward, Lynn Pearson Butler, Elena I Schwartz, Larissa A Korde
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Priscilla Kaliopi Brastianos, Albert E Kim, Anita Giobbie-Hurder, Eudocia Q Lee, Nancy U Lin, Beth A Overmoyer, Patrick Y Wen, Lakshmi Nayak, Justine V Cohen, Jorg Dietrich, April Eichler, Rebecca S Heist, Ian Krop, Donald Lawrence, Jennifer Ligibel, Sara M Tolaney, Erica L Mayer, Eric Winer, Brittany Bent, Magali A de Sauvage, Nazanin Ijad, Juliana M Larson, Braxton Marion, Sally Nason, Naina Murthy, Sherry Ratcliff, Elizabeth J Summers, Maura Mahar, Helen A Shih, Kevin Oh, Daniel P Cahill, Elizabeth R Gerstner, Ryan J Sullivan
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. Nature medicine (2023)

Sara M Tolaney.css-eqlu8i{font-size:small;padding-left:4px;} (S M Tolaney, Sara Tolaney)

Publication Activity (10 Years)

Top Topics

Top Venues

Sara M Tolaney (S M Tolaney, Sara Tolaney)